{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T20:28:39Z","timestamp":1784147319697,"version":"3.55.0"},"reference-count":40,"publisher":"American Diabetes Association","issue":"1","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,1,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>Recent experimental studies have shown that dipeptidyl peptidase 4 (DPP-4) inhibitors have antiatherosclerotic benefits in glucagon-like peptide 1\u2013dependent and \u2013independent manners. The current study investigated the effects of alogliptin, a DPP-4 inhibitor, on the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus (T2DM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>This prospective, randomized, open-label, blinded-end point, multicenter, parallel-group, comparative study included 341 patients with T2DM free of a history of apparent cardiovascular diseases recruited at 11 clinical units and randomly allocated to treatment with alogliptin (n = 172) or conventional treatment (n = 169). Primary outcomes were changes in mean common and maximum intima-media thickness (IMT) of the carotid artery measured by carotid arterial echography during a 24-month treatment period.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Alogliptin treatment had a more potent glucose-lowering effect than the conventional treatment (\u22120.3 \u00b1 0.7% vs. \u22120.1 \u00b1 0.8%, P = 0.004) without an increase of hypoglycemia. Changes in the mean common and the right and left maximum IMT of the carotid arteries were significantly greater after alogliptin treatment than after conventional treatment (\u22120.026 mm [SE 0.009] vs. 0.005 mm [SE 0.009], P = 0.022; \u22120.045 mm [SE 0.018] vs. 0.011 mm [SE 0.017], P = 0.025, and \u22120.079 mm [SE 0.018] vs. \u22120.015 mm [SE 0.018], P = 0.013, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Alogliptin treatment attenuated the progression of carotid IMT in patients with T2DM free of apparent cardiovascular disease compared with the conventional treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc15-0781","type":"journal-article","created":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T04:09:57Z","timestamp":1449029397000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":131,"title":["Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)"],"prefix":"10.2337","volume":"39","author":[{"given":"Tomoya","family":"Mita","sequence":"first","affiliation":[{"name":"Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan"},{"name":"Center for Molecular Diabetology, Juntendo University Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Katakami","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan"},{"name":"Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Yoshii","sequence":"additional","affiliation":[{"name":"Department of Medicine, Diabetology & Endocrinology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomio","family":"Onuma","sequence":"additional","affiliation":[{"name":"Department of Medicine, Diabetology & Endocrinology, Juntendo Tokyo Koto Geriatric Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kaneto","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Osonoi","sequence":"additional","affiliation":[{"name":"Naka Memorial Clinic, Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Shiraiwa","sequence":"additional","affiliation":[{"name":"Shiraiwa Medical Clinic, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kosugi","sequence":"additional","affiliation":[{"name":"Osaka Police Hospital, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Umayahara","sequence":"additional","affiliation":[{"name":"Osaka General Medical Center, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunehiko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Kansai Rosai Hospital, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Internal Medicine, Jiyugaoka Medical Clinic, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuichi","family":"Kuribayashi","sequence":"additional","affiliation":[{"name":"Misaki Naika Clinic, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Jinnouchi","sequence":"additional","affiliation":[{"name":"Jinnouchi Hospital, Kumamoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Gosho","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial and Clinical Epidemiology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Watada","sequence":"additional","affiliation":[{"name":"Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Tokyo, Japan"},{"name":"Center for Molecular Diabetology, Juntendo University Graduate School of Medicine, Tokyo, Japan"},{"name":"Center for Therapeutic Innovations in Diabetes, Juntendo University Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2015,12,1]]},"reference":[{"key":"2022031222222040200_B1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJM199807233390404","article-title":"Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction","volume":"339","author":"Haffner","year":"1998","journal-title":"N Engl J Med"},{"key":"2022031222222040200_B2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"2022031222222040200_B3","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"2022031222222040200_B4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7326\/0003-4819-147-6-200709180-00178","article-title":"Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus","volume":"147","author":"Bolen","year":"2007","journal-title":"Ann Intern Med"},{"key":"2022031222222040200_B5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrendo.2009.48","article-title":"Incretin-based therapies for type 2 diabetes mellitus","volume":"5","author":"Lovshin","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"2022031222222040200_B6","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"key":"2022031222222040200_B7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2010.12.131","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury","volume":"405","author":"Goto","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"2022031222222040200_B8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/1479164113481817","article-title":"The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-\/-) mouse model","volume":"10","author":"Gaspari","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"2022031222222040200_B9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bph.12490","article-title":"Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration","volume":"171","author":"Wang","year":"2014","journal-title":"Br J Pharmacol"},{"key":"2022031222222040200_B10","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jacc.2011.07.053","article-title":"A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice","volume":"59","author":"Matsubara","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2022031222222040200_B11","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1210\/en.2012-1855","article-title":"Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice","volume":"154","author":"Ervinna","year":"2013","journal-title":"Endocrinology"},{"key":"2022031222222040200_B12","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1161\/CIRCULATIONAHA.111.041418","article-title":"Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis","volume":"124","author":"Shah","year":"2011","journal-title":"Circulation"},{"key":"2022031222222040200_B13","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031222222040200_B14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"2022031222222040200_B15","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031222222040200_B16","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031222222040200_B17","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2337\/diacare.23.9.1310","article-title":"Carotid intima-media thickness in Japanese type 2 diabetic subjects: predictors of progression and relationship with incident coronary heart disease","volume":"23","author":"Yamasaki","year":"2000","journal-title":"Diabetes Care"},{"key":"2022031222222040200_B18","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2337\/dc11-1333","article-title":"Combination of the Framingham risk score and carotid intima-media thickness improves the prediction of cardiovascular events in patients with type 2 diabetes","volume":"35","author":"Yoshida","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031222222040200_B19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.diabres.2013.06.008","article-title":"Carotid intima-media thickness progression predicts cardiovascular events in Japanese patients with type 2 diabetes","volume":"101","author":"Okayama","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"key":"2022031222222040200_B20","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5551\/jat.18333","article-title":"Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)","volume":"20","author":"Katakami","year":"2013","journal-title":"J Atheroscler Thromb"},{"key":"2022031222222040200_B21"},{"key":"2022031222222040200_B22","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.amjhyper.2006.05.010","article-title":"Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope","volume":"19","author":"Yanase","year":"2006","journal-title":"Am J Hypertens"},{"key":"2022031222222040200_B23","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","article-title":"Revised equations for estimated GFR from serum creatinine in Japan","volume":"53","author":"Matsuo","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2022031222222040200_B24","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1161\/01.STR.0000236632.58323.cd","article-title":"Recent advances of intervention to inhibit progression of carotid intima-media thickness in patients with type 2 diabetes mellitus","volume":"37","author":"Yokoyama","year":"2006","journal-title":"Stroke"},{"key":"2022031222222040200_B25","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.2337\/dc12-0199","article-title":"Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition","volume":"35","author":"Rizzo","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031222222040200_B26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.metabol.2014.06.004","article-title":"Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes","volume":"63","author":"Tremblay","year":"2014","journal-title":"Metabolism"},{"key":"2022031222222040200_B27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.metabol.2012.09.004","article-title":"A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients","volume":"62","author":"Satoh-Asahara","year":"2013","journal-title":"Metabolism"},{"key":"2022031222222040200_B28","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.metabol.2006.01.016","article-title":"An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients","volume":"55","author":"Satoh","year":"2006","journal-title":"Metabolism"},{"key":"2022031222222040200_B29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ijcard.2008.12.213","article-title":"Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study","volume":"142","author":"Gensini","year":"2010","journal-title":"Int J Cardiol"},{"key":"2022031222222040200_B30","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2337\/db14-1149","article-title":"Sirtuin 6 expression and inflammatory activity in diabetic atherosclerotic plaques: effects of incretin treatment","volume":"64","author":"Balestrieri","year":"2015","journal-title":"Diabetes"},{"key":"2022031222222040200_B31","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1161\/01.CIR.0000165072.01672.21","article-title":"Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study","volume":"111","author":"Langenfeld","year":"2005","journal-title":"Circulation"},{"key":"2022031222222040200_B32","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1210\/jcem.86.7.7810","article-title":"Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes","volume":"86","author":"Koshiyama","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031222222040200_B33","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1001\/jama.296.21.joc60158","article-title":"Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial","volume":"296","author":"Mazzone","year":"2006","journal-title":"JAMA"},{"key":"2022031222222040200_B34","author":"Wang","year":"2011"},{"key":"2022031222222040200_B35","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice","volume":"54","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"key":"2022031222222040200_B36","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.2337\/dc10-0187","article-title":"The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha","volume":"33","author":"Fadini","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031222222040200_B37","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1016\/j.jacc.2008.10.031","article-title":"Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial","volume":"52","author":"Fleg","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2022031222222040200_B38","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.atherosclerosis.2012.12.018","article-title":"Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors","volume":"227","author":"Barbieri","year":"2013","journal-title":"Atherosclerosis"},{"key":"2022031222222040200_B39","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.amjcard.2014.04.050","article-title":"Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus","volume":"114","author":"Ishikawa","year":"2014","journal-title":"Am J Cardiol"},{"key":"2022031222222040200_B40","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(12)60441-3","article-title":"Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data","volume":"379","author":"Lorenz","year":"2012","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.2337\/dc17-er06b","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000}}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/1\/139\/624958\/dc150781.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/39\/1\/139\/624958\/dc150781.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T00:36:54Z","timestamp":1647131814000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/39\/1\/139\/31730\/Alogliptin-a-Dipeptidyl-Peptidase-4-Inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,1]]},"published-print":{"date-parts":[[2016,1,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc15-0781","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,1]]}}}